Mov Disord Vol 31, Suppl 2 Archives - Page 48 of 207 - MDS Abstracts

2016 International Congress
Tracking Parkinson’s disease over 2-6 years with MRI
T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, T.L. Pitcher, K. Wood, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)
Objective: To track Parkinson's progression over 2-6 years using global MRI measures. Background: Parkinson's is associated with accelerated brain atrophy, but the relative contribution of…
2016 International Congress
Multi-modal imaging in Parkinson’s disease patients with freezing of gait
J.M. Hall, C. O'Callaghan, J.M. Shine, M. Gilat, C.C. Walton, K.A. Ehgoetz Martens, A.A. Moustafa, S.J.G. Lewis (Milperra, Australia)
Objective: The objective of the current study is to refine understanding of the pathophysiological mechanisms underlying freezing of gait (FOG) in Parkinson's disease (PD) using…
2016 International Congress
Depressive disorders in Parkinson’s disease and Alzheimer’s disease
D. Tolibov, G. Rakhimbaeva (Tashkent, Uzbekistan)
Objective: Our primary aim was to study of the clinical characteristics of DD in patients with AD and PD. Background: The problem of a combination…
2016 International Congress
Cognitive deficits in Parkinson’s disease: A preliminary study of neuropsychological profiles
R.J. Giannaula, P.G. Sanz, J.C. Maiques, M.B. Seijas, M.J. González Aguilar, L. Grasso (Buenos Aires, Argentina)
Objective: The purpose of this project was to examine cognitive deficits in a patient sample fulfilling the diagnostic criteria for idiopathic non-demented Parkinson's disease (PD)…
2016 International Congress
Decline in drawing ability associated with frontal dysfunction after subthalamic nucleus deep brain stimulation in Parkinson’s disease
S. Hirano, S. Furukawa, M. Asahina, T. Yamamoto, T. Uchiyama, Y. Yamanaka, Y. Higuchi, T. Horikoshi, T. Uno, N. Saeki, S. Kuwabara (Chiba, Japan)
Objective: The aim of the present study was to elucidate the properties of drawing ability in Parkinson's disease (PD) patients after bilateral subthalamic nucleus deep…
2016 International Congress
Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation
S. Singh, P. Kumar (Moga, India)
Objective: (1) Curcumin is well tolerated phenolic compound used for CNS disorder but problem is its low oral bioavailability and (2) Piperine is combined to…
2016 International Congress
Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease
A. Pilotto, E. Premi, S.P. Caminiti, L. Presotto, R. Turrone, A. Alberici, B. Paghera, B. Borroni, D. Perani, A. Padovani (Brescia, Italy)
Objective: To evaluate [18]FDG-PET single-subject perfusion patterns in Parkinson's disease (PD) patients and their relationship with cognitive dysfunction and progression during five years of follow-up.…
2016 International Congress
Response inhibition in Parkinson’s disease
J. Kim, K. Zhang, M.A.I.U.A. Cruadhlaoich, S. YorkWilliams, V. Menon, K.L. Poston (Stanford, CA, USA)
Objective: To study the brain networks underlying Response Inhibition in Parkinson's disease (PD). Background: While some PD patients can have significant executive dysfunction, others remain…
2016 International Congress
Fall prediction in Parkinson’s disease based on motor dual-tasking: Evidence from the prospective MODEP study
S. Heinzel, M. Maechtel, S.E. Hasmann, M.A. Hobert, T. Heger, D. Berg, W. Maetzler (Tübingen, Germany)
Objective: To evaluate the predictive value of dual-task performance for future falls in patients with Parkinson's disease (PD). Background: Falls entail very severe health-related consequences…
2016 International Congress
Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease
C. Gasca-Salas, M. Cohn, J.A. Pineda, J.A. Obeso (Madrid, Spain)
Objective: We aimed to identify if an impairment of the cube copy of the Montreal Cognitive assessment (MoCA) was associated with worse cognitive status in…